drugset / Trial / NCT02387866

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

NCT02387866

Phase 1 Completed 62 enrolled Celgene Corporation
Non-randomizedParallel-groupOpen-labelOther

Summary

This is a single ascending dose, open-label study that will evaluate the pharmacokinetics and safety of the AG-221 compound in normal, healthy volunteer male subjects (both Japanese and Caucasian).

Timeline

Start
2015-03-02
Primary completion
2015-05-21
Completion
2015-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Enasidenib Small molecule 50 mg Oral
Subject Enasidenib Small molecule 100 mg Oral
Subject Enasidenib Small molecule 300 mg Oral

Indications

No indication recorded.